ALS

Sep 24, 2024

The amyotrophic lateral sclerosis treatment landscape is stringent and includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy, and others. The approved drugs for amyotrophic lateral sclerosis treatment include RILUZOLE, RADICAVA, TIGLUTIK, EXSERVAN, ...

Sep 24, 2024

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness, paralysis, and ultimately, death. Over the past decade, a growing understanding of the disease's underlying mechanisms has led to significant adv...

May 02, 2023

FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS The FDA has granted priority review to a supplemental biologics license application (sBLA) seeking to expand the current indication of luspatercept-aamt (Reblozyl) to include treatment of anemia in patients with very ...

Nov 15, 2022

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

Feb 23, 2021

Clover Biopharmaceuticals Raises $230 Million  Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the company during the last year over USD 400 million. The Series C round was co-led by GL Ventures and Temasek, with partic...

Jan 22, 2019

Stopping breast cancer metastasis by killing tumor cells in their sleep Oncology researchers believed that dormant breast cancer cells are not responsive to chemotherapy. But these inactive cancer cells can be active at any time and cause life-threatening metastases. Scientists at the Fred Hutchinson Cancer Rese...

Oct 11, 2018

Streamlined solutions provided by Cognitive Clinical Trials (CCT) related to the treatment and prevention of Alzheimer’s disease Congnitive Clinical Trials (CCT) has introduced a new research model that prevail over the top obstacles being faced by the researchers related to the treatment and prevention of Alzheime...

Sep 19, 2017

Thrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its Phase I trial investigating TS01, which is a new-generation clot-dissolving therapy for the treatment of clot-induced diseases like i...

Aug 26, 2016

The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional  $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The...